508 related articles for article (PubMed ID: 25847050)
1. Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort.
Lagunju I; Brown BJ; Sodeinde O
Pediatr Blood Cancer; 2015 Sep; 62(9):1587-91. PubMed ID: 25847050
[TBL] [Abstract][Full Text] [Related]
2. Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea.
Lagunju I; Brown BJ; Oyinlade AO; Asinobi A; Ibeh J; Esione A; Sodeinde OO
Pediatr Blood Cancer; 2019 Mar; 66(3):e27252. PubMed ID: 29797633
[TBL] [Abstract][Full Text] [Related]
3. Changes in Transcranial Doppler Flow Velocities in Children with Sickle Cell Disease: The Impact of Hydroxyurea Therapy.
Adegoke SA; Macedo-Campos RS; Braga JAP; Figueiredo MS; Silva GS
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):425-431. PubMed ID: 29056404
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease.
Kratovil T; Bulas D; Driscoll MC; Speller-Brown B; McCarter R; Minniti CP
Pediatr Blood Cancer; 2006 Dec; 47(7):894-900. PubMed ID: 16526051
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia.
Zimmerman SA; Schultz WH; Burgett S; Mortier NA; Ware RE
Blood; 2007 Aug; 110(3):1043-7. PubMed ID: 17429008
[TBL] [Abstract][Full Text] [Related]
6. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
Ware RE; Davis BR; Schultz WH; Brown RC; Aygun B; Sarnaik S; Odame I; Fuh B; George A; Owen W; Luchtman-Jones L; Rogers ZR; Hilliard L; Gauger C; Piccone C; Lee MT; Kwiatkowski JL; Jackson S; Miller ST; Roberts C; Heeney MM; Kalfa TA; Nelson S; Imran H; Nottage K; Alvarez O; Rhodes M; Thompson AA; Rothman JA; Helton KJ; Roberts D; Coleman J; Bonner MJ; Kutlar A; Patel N; Wood J; Piller L; Wei P; Luden J; Mortier NA; Stuber SE; Luban NLC; Cohen AR; Pressel S; Adams RJ
Lancet; 2016 Feb; 387(10019):661-670. PubMed ID: 26670617
[TBL] [Abstract][Full Text] [Related]
7. Transcranial Doppler screening in Nigerian children with sickle cell disease: A 10-year longitudinal study on the SPPIBA cohort.
Lagunju IA; Labaeka A; Ibeh JN; Orimadegun AE; Brown BJ; Sodeinde OO
Pediatr Blood Cancer; 2021 Apr; 68(4):e28906. PubMed ID: 33522690
[TBL] [Abstract][Full Text] [Related]
8. Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia.
Ghafuri DL; Chaturvedi S; Rodeghier M; Stimpson SJ; McClain B; Byrd J; DeBaun MR
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035747
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of transcranial Doppler abnormalities in Nigerian children with sickle cell disease.
Lagunju I; Sodeinde O; Telfer P
Am J Hematol; 2012 May; 87(5):544-7. PubMed ID: 22460323
[TBL] [Abstract][Full Text] [Related]
10. Transcranial Doppler ultrasonography in children with sickle cell anemia: Clinical and laboratory correlates for elevated blood flow velocities.
Lagunju I; Sodeinde O; Brown B; Akinbami F; Adedokun B
J Clin Ultrasound; 2014 Feb; 42(2):89-95. PubMed ID: 24166013
[TBL] [Abstract][Full Text] [Related]
11. Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial.
Rankine-Mullings A; Reid M; Soares D; Taylor-Bryan C; Wisdom-Phipps M; Aldred K; Latham T; Schultz WH; Knight-Madden J; Badaloo A; Lane A; Adams RJ; Ware RE
Br J Haematol; 2021 Nov; 195(4):612-620. PubMed ID: 34291449
[TBL] [Abstract][Full Text] [Related]
12. What drives transcranial Doppler velocity improvement in paediatric sickle cell anaemia: analysis from the Sickle Cell Clinical Research and Intervention Program (SCCRIP) longitudinal cohort study.
Estepp JH; Cong Z; Agodoa I; Kang G; Ding J; McCarville MB; Hankins JS; Wang WC
Br J Haematol; 2021 Jul; 194(2):463-468. PubMed ID: 34131902
[TBL] [Abstract][Full Text] [Related]
13. Haemoglobin oxygen saturation, leucocyte count and lactate dehydrogenase are predictors of elevated cerebral blood flow velocity in Nigerian children with sickle cell anaemia.
Ojewunmi OO; Adeyemo TA; Osuntoki AA; Imaga NA; Oyetunji AI
Paediatr Int Child Health; 2018 Feb; 38(1):34-39. PubMed ID: 28388354
[TBL] [Abstract][Full Text] [Related]
14. Capacity building and stroke risk assessment in Nigerian children with sickle cell anaemia.
Soyebi K; Adeyemo T; Ojewunmi O; James F; Adefalujo K; Akinyanju O
Pediatr Blood Cancer; 2014 Dec; 61(12):2263-6. PubMed ID: 25174615
[TBL] [Abstract][Full Text] [Related]
15. Association of Matched Sibling Donor Hematopoietic Stem Cell Transplantation With Transcranial Doppler Velocities in Children With Sickle Cell Anemia.
Bernaudin F; Verlhac S; Peffault de Latour R; Dalle JH; Brousse V; Petras E; Thuret I; Paillard C; Neven B; Galambrun C; Divialle-Doumdo L; Pondarré C; Guitton C; Missud F; Runel C; Jubert C; Elana G; Ducros-Miralles E; Drain E; Taïeb O; Arnaud C; Kamdem A; Malric A; Elmaleh-Bergès M; Vasile M; Leveillé E; Socié G; Chevret S;
JAMA; 2019 Jan; 321(3):266-276. PubMed ID: 30667500
[TBL] [Abstract][Full Text] [Related]
16. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trial.
Hankins JS; McCarville MB; Rankine-Mullings A; Reid ME; Lobo CL; Moura PG; Ali S; Soares DP; Aldred K; Jay DW; Aygun B; Bennett J; Kang G; Goldsmith JC; Smeltzer MP; Boyett JM; Ware RE
Am J Hematol; 2015 Dec; 90(12):1099-105. PubMed ID: 26414435
[TBL] [Abstract][Full Text] [Related]
17. Intra-individual variation in blood flow velocities in cerebral arteries of children with sickle cell disease.
Brambilla DJ; Miller ST; Adams RJ
Pediatr Blood Cancer; 2007 Sep; 49(3):318-22. PubMed ID: 17243135
[TBL] [Abstract][Full Text] [Related]
18. Transcranial Doppler velocity and brain MRI/MRA changes in children with sickle cell anemia on chronic transfusions to prevent primary stroke.
Sheehan VA; Hansbury EN; Smeltzer MP; Fortner G; McCarville MB; Aygun B
Pediatr Blood Cancer; 2013 Sep; 60(9):1499-502. PubMed ID: 23625812
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial.
Ambrose EE; Latham TS; Songoro P; Charles M; Lane AC; Stuber SE; Makubi AN; Ware RE; Smart LR
Lancet Haematol; 2023 Apr; 10(4):e261-e271. PubMed ID: 36870358
[TBL] [Abstract][Full Text] [Related]
20. Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell Anemia.
Jeste ND; Sánchez LM; Urcuyo GS; Bergés ME; Luden JP; Stuber SE; Latham TS; Mena R; Nieves RM; Ware RE
JMIR Res Protoc; 2017 Jun; 6(6):e107. PubMed ID: 28576754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
